Kangmei launched the re-election of the board of directors, and the Guangzhou Pharmaceutical Department is officially in sight

  Yangcheng Evening News reporter Chen Zeyun

  After Kangmei Pharmaceutical's debts have been fully paid off, its follow-up business issues have been attracting attention.

On January 7, the first interim meeting of the eighth board of directors of Kangmei Pharmaceutical in 2022 and the first interim meeting of the eighth board of supervisors in 2022 were held in Guangzhou Branch.

On the evening of the same day, *ST Kangmei (600518) issued a number of announcements on the nomination of candidates for the board of directors and the board of supervisors. The non-independent directors of the new board members are from GPHL, Guangdong Finance Holdings, Guangdong Hengjian and Jieyang Jinye.

This means that the Guangzhou Pharmaceutical Department will officially enter Kangmei.

As of January 7, *ST Kangmei welcomed the new owner with a cumulative increase of 18.73% in 7 trading days.

  GPHL led Kangmei to change the board of directors, supervisors and senior executives

  The announcement shows that *ST Kangmei's board of directors has passed a resolution to nominate Lai Zhijian, Mi Qi, Liu Guowei, Liang Jun, Yang Weirong, and Fang Miaoshuang as candidates for the company's ninth board of directors as non-independent directors.

At the same time, the list of new independent directors and members of the Supervisory Committee of *ST Kangmei has also been basically determined: Luo Tao, Lai Xiaoping and Zeng Qing are nominated as candidates for independent directors of the board of directors; Gao Yanzhu and Wang Tong are nominated as candidates for non-employee representative supervisors of the Supervisory Committee. ; recommended Huang Longtao as the candidate for the employee supervisor of the board of supervisors.

  Judging from the candidates' resumes, among the new board members of *ST Kangmei, the three non-independent directors Lai Zhijian, Mi Qi and Liu Guowei are all from GPHL.

Among them, Lai Zhijian is currently the deputy director of quality, director of technology and quality department, and director of safety production development department of GPHL.

Mi Qi is currently the Secretary and Director of the Disciplinary Committee of Guangzhou Pharmaceutical Co., Ltd., an important subsidiary of GPHL in the commercial sector.

Liu Guowei has successively served as a member of the party committee, director and general manager of Guangzhou Caizhilin Pharmaceutical Co., Ltd., and the executive director and general manager of Guangzhou Shennong Traditional Chinese Medicine Development Co., Ltd.

Since October 2020, he has served as the director and general manager of *ST Kangmei.

The remaining directors, Liang Jun, Yang Weirong, and Fang Miaoshuang, were dispatched by the shareholders of Shennong, Guangdong Yuecai, Jinye Development, etc., and have very rich professional experience in capital operation and financial management.

  It is reported that in order to ensure the stable development of *ST Kangmei, GPHL has previously sent a team of more than 100 people to support the production and operation of Kangmei Pharmaceutical in the stage of entrusting Kangmei. Work experience in GPHL.

After the re-election work is completed according to the relevant procedures, the members of the new board of directors and the board of supervisors of Kangmei will become the core strength of the company's future planning, decision-making, governance and development.

  Guangyao Kangmei accelerates the pace of coordinated development

  *ST Kangmei's bankruptcy reorganization work lasted for more than a year, and the bankruptcy reorganization plan was completed at the end of last year.

After review by the Intermediate People's Court of Jieyang City, Guangdong Province, all the debts of Kangmei Pharmaceutical have been 100% repaid through cash, shares, trust rights and other methods.

  *ST Kangmei stated in the announcement issued on the evening of December 30, 2021 that after the implementation of the reorganization plan, with the resolution of the debt crisis and the support of investors, the company will gradually restore the ability to continue operations and profitability, and return to a benign development track.

Following this, Guangdong Shennong also quickly took advantage of its shareholders to empower Kangmei Pharmaceutical's development.

  On January 4 this year, GPHL brought 5 million yuan of anti-epidemic materials raised by Kangmei Pharmaceutical to assist Xi'an, marking the beginning of the coordinated action between the two companies.

  Before that, from December 29th to December 31st last year, Zhang Chunbo, deputy general manager of GPHL and chairman of the investment decision-making committee of Guangdong Shennong's Management Partnership, led a team to Puning, Guangdong to conduct research and exchanges on Kangmei Pharmaceutical. There are also members of the decision-making committee, Lai Zhijian and Li Zhenglun, who are the deputy directors of quality and investment of GPHL respectively.

Among them, Lai Zhijian is one of the candidates for non-independent directors of the board of directors announced by *ST Kangmei.

  It is reported that GPHL participated in the restructuring investment of Kangmei Pharmaceutical through its wholly-owned subsidiary, Guangzhou Shennong Traditional Chinese Medicine Development Co., Ltd. (hereinafter referred to as "Guangzhou Shennong").

Guangdong Shennong Enterprise Management Partnership (hereinafter referred to as "Guangdong Shennong") invested 5.4 billion yuan, and jointly invested 6.5 billion yuan with other social capital to hold 29.90% of the shares, becoming the largest shareholder of Kangmei Pharmaceutical.

Guangdong Shennong is composed of GPHL, Guangdong Industrial Investment Fund, Hengjian Assets, Jieyang Jinye and other state-owned holding companies.

  Among them, GPHL is a state-owned enterprise in Guangzhou and the first company in the world to enter the Fortune Global 500 with traditional Chinese medicine as its main business.

After GPHL formally participates in the investment in Kangmei, how Kangmei will develop steadily with the help of GPHL in the future is highly anticipated by the industry.

  Guangdong Shennong's other partners Guangdong Property Industry Investment Fund is a wholly-owned subsidiary of the Guangdong Provincial Government, Hengjian Assets is a wholly-owned enterprise of the State-owned Assets Supervision and Administration Commission of Guangdong Province, and Jieyang Jinye is a holding company of the State-owned Assets Supervision and Administration Commission of Jieyang City.

  It is reported that Kangmei’s controlling shareholder Guangdong Shennong and its financial investors GF Securities, Guohou Assets, Zhaoping Fund, and China Resources Shenzhen International Investment Trust will fully integrate their advantageous resources and provide strong support for the development of Kangmei Pharmaceutical’s industry, so as to consolidate and improve the company’s The core business advantages of the entire pharmaceutical industry chain will gradually restore the company's product competitiveness and business competitiveness.